Fridays can be the most productive work day, as you look to shore up everything before the weekend starts.
Or, maybe instead, it’s a day filled with long lunches and listless Internet surfing, as you seek out all the interesting articles... Read more »
Biotech financing is a cyclical thing. Two years ago, the IPO window was unlatched but a number of companies ended up withdrawing their stock offerings. Others that pushed their IPOs through couldn’t sell shares at the price they wanted.
This year,... Read more »
Intel (NASDAQ: INTC) announced Thursday that CEO Brian Krzanich has resigned in the wake of the company’s recent discovery that he had been involved in a past consensual relationship with an Intel employee.
The relationship violated Intel’s non-fraternization policy—the finding... Read more »
The window for biotech IPOs remains wide open and six more companies have charged through it, raising more than $568 million in the span of 24 hours.
The first was Eidos Therapeutics (NASDAQ: EIDX), which raised $106 million in its... Read more »
The new, independent, healthcare-focused company Amazon, Berkshire Hathaway, and JPMorgan Chase plan to launch made a big splash when it was first announced in January, but few details have emerged since.
On Wednesday, the trio of American business heavyweights revealed... Read more »
Dallas—Alyce Alston, a veteran of the digital media and publishing industries, officially took over the reins of the Dallas Entrepreneur Center Wednesday.
“I’ve always been an innovator within large organizations and then with startups after that,” she says. “I have... Read more »
CrowdStrike, a Silicon Valley cybersecurity company that fends off hackers by patrolling the edge devices connected to a network, announced today it raised $200 million in a financing round that sets the company’s valuation at more than $3 billion.
Sunnyvale,... Read more »
LoftSmart, a website that helps college students find off-campus housing, has raised $12.9 million in an equity funding round, according to a securities filing.
New York-based LoftSmart lets students search for and review properties typically rented by students, leaving feedback... Read more »
Roche this morning agreed to acquire the part of Foundation Medicine it didn’t already own, another big vote of confidence in tests that analyze a patient’s cancer genes and the drugs that can target them.
Roche will pay $137 per share,... Read more »
It’s far too early to say whether gene therapy can treat Duchenne muscular dystrophy, a deadly genetic disease. But the first clinical data have arrived, with Sarepta Therapeutics today reporting encouraging preliminary results from three patients.
Sarepta (NASDAQ: SRPT), of... Read more »
[Updated, 6/19/18, 4:20 p.m. See below.] Hearing loss affects millions of Americans, but so far, drug companies have not yet brought treatments to the market. Decibel Therapeutics aims to pioneer the discovery and development of therapies addressing multiple forms... Read more »
The race to use gene therapy to treat Duchenne muscular dystrophy, a progressive, deadly genetic disease that affects boys, is heating up this week. The FDA just cleared Solid Biosciences to resume clinical testing of a Duchenne gene therapy, a day... Read more »